Wells Fargo & Company Trims UiPath (NASDAQ:PATH) Target Price to $30.00

UiPath (NASDAQ:PATHGet Rating) had its price target decreased by equities researchers at Wells Fargo & Company from $35.00 to $30.00 in a note issued to investors on Wednesday, The Fly reports. Wells Fargo & Company‘s price objective indicates a potential upside of 73.91% from the company’s current price.

Several other research analysts also recently issued reports on PATH. Morgan Stanley cut their price objective on UiPath from $74.00 to $41.00 and set an “overweight” rating for the company in a research report on Thursday, March 31st. Canaccord Genuity Group cut their price objective on UiPath from $55.00 to $30.00 in a research report on Thursday, March 31st. Oppenheimer cut their price objective on UiPath from $56.00 to $35.00 and set an “outperform” rating for the company in a research report on Thursday, March 31st. Canaccord Genuity Group lowered their target price on shares of UiPath from $55.00 to $30.00 and set a “hold” rating for the company in a research note on Thursday, March 31st. Finally, Credit Suisse Group lowered their target price on shares of UiPath from $75.00 to $57.50 and set an “outperform” rating for the company in a research note on Thursday, March 31st. Three research analysts have rated the stock with a sell rating, six have assigned a hold rating and twelve have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $42.38.

Shares of PATH stock traded up $0.19 during midday trading on Wednesday, reaching $17.25. 64,720 shares of the company traded hands, compared to its average volume of 7,770,972. The firm’s 50 day simple moving average is $21.97 and its two-hundred day simple moving average is $34.88. UiPath has a 1-year low of $13.66 and a 1-year high of $90.00. The firm has a market cap of $9.35 billion and a PE ratio of -10.52.

UiPath (NASDAQ:PATHGet Rating) last posted its quarterly earnings results on Wednesday, March 30th. The healthcare company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.08). UiPath had a negative net margin of 58.91% and a negative return on equity of 21.20%. The company had revenue of $289.70 million for the quarter, compared to analyst estimates of $283.25 million. The company’s revenue for the quarter was up 39.3% on a year-over-year basis. As a group, equities research analysts expect that UiPath will post -0.46 EPS for the current year.

In related news, Director Rich Wong sold 75,000 shares of the stock in a transaction that occurred on Friday, February 18th. The shares were sold at an average price of $37.81, for a total transaction of $2,835,750.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Kimberly Hammonds sold 2,521 shares of the company’s stock in a transaction that occurred on Friday, March 18th. The shares were sold at an average price of $28.19, for a total transaction of $71,066.99. The disclosure for this sale can be found here. 31.88% of the stock is currently owned by corporate insiders.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Baldwin Brothers LLC MA acquired a new position in UiPath in the 4th quarter worth about $26,000. Prospera Financial Services Inc bought a new stake in shares of UiPath in the 1st quarter valued at approximately $27,000. Sterling Investment Advisors Ltd. bought a new stake in shares of UiPath in the 4th quarter valued at approximately $30,000. CarsonAllaria Wealth Management Ltd. bought a new stake in shares of UiPath in the 4th quarter valued at approximately $30,000. Finally, Benjamin Edwards Inc. grew its stake in shares of UiPath by 65.4% in the 4th quarter. Benjamin Edwards Inc. now owns 708 shares of the healthcare company’s stock valued at $31,000 after buying an additional 280 shares in the last quarter. 52.19% of the stock is owned by hedge funds and other institutional investors.

About UiPath (Get Rating)

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, and Japan. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.

Featured Stories

The Fly logo

Analyst Recommendations for UiPath (NASDAQ:PATH)

Receive News & Ratings for UiPath Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UiPath and related companies with MarketBeat.com's FREE daily email newsletter.